RUNX1 Research Program

🌟 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗥𝗨𝗡𝗫𝟭-𝗙𝗣𝗗 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀! 🌟 The National Cancer Institute (NCI) is conducting a Phase 1b trial to treat RUNX1-FPD patients with imatinib. This study aims to find the safest dose that can be tolerated while potentially increasing RUNX1 protein levels, and if imatinib can improve blood health and reduce cancer risk in RUNX1-FPD patients. 🔗 Learn more: https://lnkd.in/gheftDxA #RUNX1FPD #ClinicalTrials #BloodCancerResearch #Imatinib

Please join us 𝗧𝗢𝗗𝗔𝗬 at 12pm ET for an update on The National Institutes of Health's #RUNX1 Natural History Study Update* with Dr. David Young. Register here: https://bit.ly/4fibaKm *𝘗𝘭𝘦𝘢𝘴𝘦 𝘯𝘰𝘵𝘦: 𝘛𝘩𝘪𝘴 𝘸𝘦𝘣𝘪𝘯𝘢𝘳 𝘪𝘴 𝘵𝘢𝘪𝘭𝘰𝘳𝘦𝘥 𝘧𝘰𝘳 𝘢 𝘨𝘦𝘯𝘦𝘳𝘢𝘭 𝘢𝘶𝘥𝘪𝘦𝘯𝘤𝘦.

Join us for the second presentation on this clinical trial, sponsored by RRP at MD Anderson Cancer Center, evaluating the safety and feasibility of collecting and banking blood stem cells from #RUNX1FPD patients. Following the presentation will be a Q&A session with Dr. Chitra Hosing, principal investigator on the study. If you’re interested in learning more about this important study, register today! https://lnkd.in/gW6tgmTQ #ClinicalTrials #Hematology

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸! Join a Zoom meeting on Wednesday, October 23rd at 4 p.m. ET with Dr. Paul Liu of the National Human Genome Research Institute (NHGRI) to hear the latest research findings from The National Institutes of Health's RUNX1 Natural History Study. Register here: https://bit.ly/47u8jvr

🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗥𝗨𝗡𝗫𝟭-𝗙𝗣𝗗 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀! 🌟 The NIH RUNX1 Clinical Research study offers a unique chance to monitor cancer development from a pre-cancer stage in real-time. The goal? To identify factors that differentiate those who develop cancer from those who don’t, paving the way for better risk assessment and prevention strategies. 🔗 Learn more: https://lnkd.in/gprt3--Z #RUNX1FPD #BloodCancerResearch #NIHStudy

RRP and @AlexsLemonade are accepting applications for the Early Career Investigator Grant now through Thurs, Dec 19th, before 8 pm ET. The grant supports research to prevent #preleukemia from progressing to #leukemia in #RUNX1FPD patients. Apply today: https://bit.ly/3NkdHbk

Join us on Wednesday, October 23rd at 4 p.m. EDT for a special Zoom presentation by the National Institutes of Health’s Dr. Paul Liu, who will provide the latest updates on clinical and genomic data from the NIH RUNX1 Natural History Study. If you’re studying RUNX1-FPD or providing care for patients with this condition, this is a must-attend session. 🔗 Register here: https://bit.ly/47u8jvr

The RUNX1 Research Program is proud to partner with the American Cancer Society to launch the LEAP grant program, which offers over $2.8 million in funding. This initiative is dedicated to supporting innovative research in the interception and prevention of blood cancers, particularly for individuals with #RUNX1FPD. If you’re conducting research in this critical area, we encourage you to apply by Oct 29. Find out more and apply here: https://bit.ly/liLEAPGrant #CancerResearch #LeukemiaPrevention #RUNX1FPD #GrantOpportunity

🌟 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗥𝗨𝗡𝗫𝟭-𝗙𝗣𝗗 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀! 🌟 Have you had surgeries or biopsies in the past? Your leftover tissue samples could be key to advancing RUNX1-FPD research. Access to these biospecimens can greatly accelerate our understanding of this rare disease. If you're open to researchers contacting your doctors about any leftover samples, please fill out this form. This doesn't commit you to sharing, but let's discuss the possibility! 🔗 Learn more here: https://lnkd.in/gR2yDakJ #RUNX1FPD #RareDiseaseResearch #Biospecimens

Countdown Alert! In just 𝗢𝗡𝗘 𝗛𝗢𝗨𝗥, our second #Spanish HHM Webinar is happening on Monday, September 23 at 1:00 PM ET. Dr. Ximena Jordan from the University of Pennsylvania will be presenting, followed by a Q&A with Drs. Sofía Grille, María Díez Campelo, and María Roberta Demichelis Gómez. This is your opportunity to connect with leading professionals and ask your burning questions. Don’t miss out: https://lnkd.in/gkKHr-jq #CancerResearch #Hematology #MedicalEducation